Welcome to the Shoichet Lab
"Our research program requires a cross disciplinary approach where aspects of engineering, chemistry, and biology are applied to the fields of Regenerative Medicine, Tissue Engineering and Drug Delivery. We approach unsolved problems in medicine by creating a series of design criteria which we then use to formulate solutions."
Ontario Chief Scientist Dr. @MollyShoichet & her team (@ShoichetLab @UofT) are engineering new materials to help restore vision to people who lose their sight from diseases like age-related #maculardegeneration. Just 1 of the amazing ways #WeAreOntarioInnovation pic.twitter.com/KXaLSe1f3t
— OntarioInnovation (@OntInnovation) April 19, 2018
The Numbers
Features
Feature of the Month
August 2020 - Please join me in congratulating Amber Xue, Daniela Isaacs-Bernal, Kelti Smith and Lia Ho. Congratulations to Amber and Daniela on being awarded NSERC PROMOTE scholarships for 3 years, and Lia on being awarded a CREMS scholarship for the summer. We would like to congratulate Kelti Scholarship who…
Read more
Science Advance
A research team led by Dr. Molly Shoichet develops "piggyback" vehicle to escape endosomal trap and deliver RNA therapeutics. Their work is featured in an article in Science Advances. University of Toronto Engineering News
Read more
Connaught Innovation Award
On March 10, 2020, Dr. Molly Shoichet joins nine of her colleagues in receiving the Connaught Innovation Awards to help accelerate the development and commercialization of their promising technologies. UofT News
Read more
AmacaThera
AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has raised $3.25 million CAD in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners. AmacaThera’s founding technology was discovered at the University of Toronto by Dr. Molly Shoichet, a leading expert on polymer design. AmacaThera envisions their proprietary…
Read more
Recent Publications
Publication
“Nanoparticle delivery of a pHsensitive prodrug of doxorubicin and a mitochondrial targeting VESH8R8 synergistically kill multi-drug resistant breast cancer cells” Czupiel, P.P.; Delplace, V.; Shoichet, M.S. 2020 Scientific Reports, 10: 8726; doi: 10.1038/s41598-020-65450-x Publication
Read morePublication
“Attenuated diphtheria toxin mediates siRNA delivery” Arnold AE; Smith LJ; Beilhartz G; Bahlmann LC; Jameson E; Melnyk R; Shoichet MS. 2020 Science Advances, 6 : eaaz4848; doi: 10.1126/sciadv.aaz4848 Publication
Read more
Publication
“Non-swelling, ultra-low content inverse electron demand Diels-Alder hyaluronan hydrogels with tunable gelation time: synthesis and in vitro evaluation” Delplace V; Nickerson PEB; Ortin-Martinez A; Baker AEG; Wallace VA; Shoichet MS. 2020 Advanced Functional Materials, 1903978: 1-11; doi: 10.1002/adfm.201903978 Publication
Read more
Publication
“Designer biomaterials to model cancer cell invasion in vitro: predictive tools or just pretty pictures?” Bahlmann LC; Smith LJ; Shoichet MS. 2020 Advanced Functional Materials (invited perspective), 1909032: 1-11; doi: 10.1002/adfm.201909032 Publication
Read more
